http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
새로운 퀴놀론 항균제 DW-116의 Post-Antibiotic Effect
최금화(Keum Hwa Choi),오태권(Tae Kwon Oh),백문창(Moon Chang Baek),김병각(Byung Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1998 약학회지 Vol.42 No.2
The post-antibiotic effects (PAE) of DW-116 were evaluated against Bacillus subtilis ATCC 6633, Bacillus cereus ATCC 27348, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa MB4-16, repectively. Against gram-positive bacteria, PAEs of DW-116 were longer duration (20-35 min) than those of rufloxacin(1O-20 min), and shorter than those of ciprofloxacin (50-90 min). Especially, against E. coli, DW-116 and ciprofloxacin obtained approximately 3 hrs of PAES.
최금화(Keum Hwa Choi),오태권(Tae Gwon Oh),권애란(Ae Ran Kwon),김병각(Byong Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1999 약학회지 Vol.43 No.1
The bactericidal activities of DW-116, a new fluoroquinolone was estimated by comparing the minimal bactericidal concentrations (MBCs) of it against some Gram-positive and -negative bacterial concentration with the minimal inhibitory concentrations (MICs). The MBCs against the test organisms were equal to or two times higher than MICs. The results support that the antibacterial activity of DW-116 is bactericidal.
한국형 유산균 Bifidobacterium 속 균주의 항생물질에 대한 감수성
장현아,최금화,오태권,권애란,김동현,최응칠,Chang, Hyun-Ah,Choi, Keum-Hwa,Oh, Tae-Kwon,Kwon, Ae-Ran,Kim, Dong-Hyun,Choi, Eung-Chil 대한약학회 1998 약학회지 Vol.42 No.6
Minimal inhibitory concentrations (MICs) of Bifidobacterium spp. strains (Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525) isolated from healthy Korean against antituberculosis agents and fluoroquinolones were determined. From the MICs it was found that Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 were susceptible to rifampicin and fluoroquinolenes and resistant to other antituberculosis agents.
새로운 beta-lactam계 항생물질 개발을 위한 검정용 균주의 개발
김대진(Dae Jin Kim),최금화(Keum Hwa Choi),김숙경(Sook Kyung Kim),최성숙(Sung Sook Choi),김병각(Byung Kak Kim),강창율(Chang Yuil Kang),최응칠(Eung Chil Choi) 대한약학회 1995 약학회지 Vol.39 No.2
Clinically isolated bacterial strains resistant to almost of all the clinically superior beta-lactam antibiotics can be used to screen the promising ones among the newly synthesized beta-lactam antibiotics. To select the resistant strains, the susceptibility of 389 strains of S. aureus, 144 strains of coagulase negative staphylococci, 509 strains of E. coli, 115 strains of E. cloacae and 187 strains of P. aeruginosa to methicillin, ampicillin, piperacillin and gentamicin was determined. The susceptibility of 19 bacterial strains selected through the first screening to cefixime, cefotiam, cefotaxime, flomoxef, cepfirome, cefdnir, SCE-2787, panipenem and imipenem was determined. Four strains of S. aureus finally selected have high degree of resistance to almost of all bata-lactam antibiotics used and also produce beta-lactamases. These 4 strains of S. aurues can be used to screen effectively the promising beta-lactam antibiotics among the numerous numbers of the newly synthesized beta-lactam antibiotics.
리팜피신과 오플록사신에 내성인 Bacillus coagulans OFR17 균주
김은아(Eun Ah Kim),오태권(Tae Kwon Oh),최금화(Keum Hwa Choi),이진희(Jin Hee Lee),백문창(Moon Chang Baek),김병각(Byong Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1997 약학회지 Vol.41 No.4
The preparation of Bacillus coagulans is used as a therapeutics for human intestinal disorders. However, the bacterium in the preparation is very susceptible to rifampicin and fluoroquinolones. When the preparation is taken with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. So B. coagulans RFR17 resistant to rifampicin was obtained by treating the parent B. coagulans with N-methyl-N'-nitro-N-nitrosoguanidine. B. coagulans OFR17 was produced by serial passage of B. coagulans RFR17 on agar with 2-fold minimal inhibitory concentration of ofloxacin or ciprofloxacin. B. coagulans OFR17 was resistant to fluoroquinolones up to 16~64 fold higher than that for the original strain. B. coagulans OFR17 also exhibited identical characteristics with the parent strain when they were tested for lactic acid production and growth inhibition of E. coli MB4-01 and Shigella sonnei MB4-10411. From in vitro test, it was also identified that rifampicin and ofloxacin are not inactivated by certain factors of B. coagulans OFR17. Conclusively, B. coagulans OFR17 can be regarded as a promising strain which can be developed as the preparation for the treatment of the intestinal disorders of the tuberculosis patients under rifampicin and ofloxacin therapy.